Table 3.
Univariate analysis of transplants outcomes according to donor type.
| Outcomesa | Overall | MSD | MUDb | Haplo | P |
|---|---|---|---|---|---|
| ANC engraftment, CI at 60 days (%) | 96 (93–98) | 97 (94–100) | 94 (90–99) | 92 (85–99) | 0.003 |
| Platelet engraftment, CI at 180 days (%) | 95 (93–98) | 98 (95–100) | 95 (90–100) | 93 (86–100) | 0.01 |
| aGvHD, % (95% CI) | |||||
| grade II-IV | 21 (16–26) | 18 (12–28) | 21 (14–29) | 23 (14–34) | 0.6 |
| grade III-IV | 7 (4–11) | 6 (2–14) | 7 (3–13) | 8 (3–16) | 0.9 |
| cGvHD, % (95% CI) | |||||
| any grade | 45 (38–52) | 50 (37–62) | 37 (27–47) | 50 (36–64) | 0.1 |
| moderate-to-severe | 28 (22–34) | 35 (24–46) | 25 (17–35) | 24 (14–36) | 0.3 |
| severe | 8 (5–12) | 7 (3–14) | 8 (4–15) | 10 (4–20) | 0.8 |
| TRM, % (95% CI) | 13 (9–18) | 8 (3–15) | 14 (8–22) | 19 (10–30) | 0.1 |
| CIR, % (95% CI) | 16 (11–21) | 20 (11–31) | 16 (9–24) | 9 (4–18) | 0.4 |
| LFS, % (95% CI) | 71 (65–77) | 72 (59–82) | 71 (61–80) | 71 (57–81) | 0.6 |
| OS, % (95% CI) | 74 (68–80) | 78 (68–84) | 73 (63–82) | 72 (58–82) | 0.3 |
| GRFS, % (95% CI) | 47 (40–53) | 46 (34–57) | 48 (38–58) | 46 (32–58) | 0.9 |
aGvHD acute graft-versus-host disease, cGvHD chronic graft-versus-host disease, ANC neutrophil, 95% CI 95% confidence interval, TRM transplant-related mortality, CIR cumulative incidence of relapse/progression, LFS leukemia-free survival, OS overall survival, GRFS graft-versus-host-free/relapse-free survival.
aANC and platelet engraftment: cumulative incidence at 60 and 180 days, respectively; acute GvHD: 100-day cumulative incidence; chronic GvHD, TRM, CIR, LFS, OS, and GRFS: survival probability at 2 years.
b16 mismatched unrelated donors (MMUD) are included: outcomes for this group of patients were not statistically different from that of recipients of MUD allo-HSCT (data not shown).